{
  "report_rows": [
    {
      "kpi": "Non-GAAP EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5.80 vs. cons ~$5.61",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$9.60B vs. cons ~$9.43B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Repatha Product Sales (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.02B vs. cons ~$950M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Total Revenue Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$37.8B-$39.0B vs. cons ~$37.9B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Non-GAAP EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$22.20-$23.40 vs. cons ~$22.50 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Prolia/XGEVA Erosion Pace Commentary (Q2/FY2026)",
      "prediction": "LOWER",
      "answer": "guide ~-30% YoY decline vs. cons ~-25% YoY decline (FY2026 erosion trend)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "Stock already de-risked into the print (pulled back ~3.6% from the $393 high amid the cyber-incident disclosure), so a likely beat-and-raise on EPS/revenue plus modest guidance lift is largely pre-digested by the 15% run since May; initial pop should fade over days 2-5 as analysts net the beat against implicit FY cuts embedded in accelerating Prolia/XGEVA/Enbrel erosion, unresolved TAVNEOS withdrawal proceedings, the IRS NOPA overhang, and no new MariTide pivotal data \u2014 all limiting durable upward estimate revisions even after a headline beat.",
  "day5_confidence": "LOW"
}